No retraction, correction or concern found when last checked on Oct 31, 2026.

Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice

Alexander A. Cohen, Priyanthi N. P. Gnanapragasam, Yu E. Lee and 10 more

Science · 2021 · CC BY

doi:10.1101/2020.11.17.387092

Abstract

Fighting zoonotic coronaviruses In the past 20 years, three betacoronaviruses thought to have originated in bats have caused devastating disease in humans. The global pandemic caused by the latest such virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), highlights the need to protect against other strains that could present a threat to humans. Cohen et al. constructed nanoparticles displaying the protein domain that binds the host cell receptor (receptor-binding domain or RBD), either a homotypic SARS-CoV-2 particle or mosaic particles displaying RBDs from four or eight different betacoronaviruses. In mice, antibodies to the SARS-CoV-2 RBD were elicited just as well by mosaic particles as by homotypic nanoparticles. The mosaic nanoparticles elicited antibodies that, beyond recognizing the strains displayed, also recognized mismatched strains. Science , this issue p. 735

References 56

1.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
2.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
3.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
4.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
5.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
6.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
7.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
8.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
9.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
10.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
11.
Self-assembling protein nanoparticles in the design of vaccines · 2015
No notice
12.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
13.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
14.
Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization · 2016
No notice
15.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
16.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
17.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
18.
Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus · 2017
No notice
19.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
20.
New Routes and Opportunities for Modular Construction of Particulate Vaccines: Stick, Click, and Glue · 2018
No notice
21.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
22.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
23.
Role of Multivalency and Antigenic Threshold in Generating Protective Antibody Responses · 2019
No notice
24.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
25.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
26.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
27.
A new coronavirus associated with human respiratory disease in China · 2020
Corrected
28.
A pneumonia outbreak associated with a new coronavirus of probable bat origin · 2020
No notice
29.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
30.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
31.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
32.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
33.
Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays · 2020
No notice
34.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
35.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
36.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
37.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
38.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
39.
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability · 2020
No notice
40.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
41.
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model · 2020
No notice
42.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
43.
Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies · 2020
No notice
44.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
45.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
46.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
47.
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses · 2020
No notice
48.
Structure-based design of prefusion-stabilized SARS-CoV-2 spikes · 2020
No notice
49.
Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding · 2020
No notice
50.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
51.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
52.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
53.
A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone · 2020
No notice
54.
Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2 · 2020
No notice
55.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
56.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library

Cited by papers we hold 7

A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies · 2022
No notice
Vaccination with SARS-CoV-2 spike protein lacking glycan shields elicits enhanced protective responses in animal models · 2022
No notice
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection · 2022
No notice
Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models · 2022
No notice
Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines · 2022
No notice
Vaccines against Covid-19: Comparison, Limitations, the Decrease of Pandemic and the Perspective of Viral Respiratory · 2021
Not checked
Scientific rationale for developing potent RBD-based vaccines targeting COVID-19 · 2021
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.